Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer’s disease (AD), a leading neurodegenerative disorder, progresses from an intermediary stage known as Mild Cognitive Impairment (MCI), characterized by measurable cognitive decline with retained functional independence.
Why it matters
This deep learning framework was designed to predict progression from mild cognitive impairment to Alzheimer's disease using longitudinal structural MRI scans. It is a prediction tool only and does not test any treatment, cure or prevention.
-
This analysis found that the mean brain age gap does not significantly differ between Quintile 5 and Quintiles 1‐4 (p≤0.45), however statistical power was low given very broad confidence intervals.
Why it matters
This study tested the relationship between neighborhood disadvantage and accelerated brain aging using brain age gap estimates in 1052 Wisconsin participants. It found that the mean brain age gap did not significantly differ between the most disadvantaged quintile and the other quintiles, though statistical power was low given very broad confidence intervals.
-
49/100
In 2022, the overall prevalence of homebound beneficiaries was 22.0% (8.4% of beneficiaries were homebound, and 13.6% were semihomebound).
Why it matters
This study found that 22 percent of Medicare Advantage beneficiaries were homebound or semihomebound, and dementia was predictive of homebound status. It does not test any treatment, cure, or prevention for Alzheimer's disease, and it suggests findings can inform strategies to identify and manage care for homebound beneficiaries.
-
memantine, cholinesterase inhibitor (ChEI), antipsychotic use] estimated adjusted odds ratios (aOR) and 95% CIs for resident, facility, and HRR characteristics.
Why it matters
This study found regional differences in the use of antipsychotic and antidementia medications among nursing home residents with dementia. It suggests that evidence-based protocols are needed to guide the use of these medications, but it does not test any treatment for curing or preventing Alzheimer's disease.
-
49/100
PA policies varied substantially across private insurers in the US.
Why it matters
This cross-sectional analysis found that Medicare Advantage insurers required prior authorization for 17% to 33% of traditional Medicare Part B spending, with substantial differences between insurers. It contains no research findings on treating, curing, or preventing Alzheimer's disease.
-
The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia.
Why it matters
In 452 older adults from the MAPT trial, higher plasma adropin concentrations were linked to lower risk of cognitive decline. This is an observational biomarker finding and does not show that raising adropin treats, cures or prevents Alzheimer's disease.
-
Studies examining associations between greenspace and Alzheimer’s disease and related dementia (ADRD) outcomes are rapidly on the rise, yet no known literature reviews have summarized the racialized/ethnic group and geographic variation of those published studies.
Why it matters
This rapid review found that few studies on neighborhood greenspace and brain health included racialized or ethnic groups or were conducted in developing countries, and almost none examined group differences. It does not test any treatment, cure or prevention, but identifies gaps in the research.
-
Multimorbidity (the presence of two or more long-term conditions [LTCs]) was suggested to exacerbate the neuronal injuries.
Why it matters
This large prospective study looked at whether having two or more long-term health conditions is linked to a higher risk of dementia. It does not show that treating those conditions prevents dementia, only that an association was found.
-
According to the National Institute on Aging (NIA), there are more than 70 associated genes or genetic areas associated with Alzheimer’s when 20 years ago, we knew of only four (Hodes, 2022).
Why it matters
This paper describes a training program for early-career researchers studying health disparities in Alzheimer's disease and related dementias. It does not test any treatment, cure, or prevention.
-
49/100
The hippocampus has a well-established role in spatial and episodic memory but a broader function has been proposed including aspects of perception and relational processing.
Why it matters
This review describes evidence that the hippocampus responds to sound and interacts with auditory processing across species, suggesting broader contributions to perception and cognition beyond spatial and episodic memory. It mentions possible future applications such as entraining hippocampal rhythms, but reports nothing about treating, curing, or preventing Alzheimer's disease.
-
On clinical data, this innovative approach for early diagnosis might provide more insight into pathophysiological processes underlying degenerative changes, as well as toward a personalized risk evaluation for pharmacological, nonpharmacological, and rehabilitation treatments.
Why it matters
This article discusses using graph analysis and machine learning on EEG and other biomarkers to identify features of brain aging and support early dementia diagnosis and risk evaluation. It concerns diagnosis and risk prediction, not treating, curing, or preventing Alzheimer's disease.
-
Frailty and dementia are associated with poor health outcomes and increased health care utilization.
Why it matters
This study shows that Medicare beneficiaries with both frailty and dementia had higher mortality, less time at home, more ICU stays, and higher costs than those with either condition alone. It suggests that improving health care delivery for this group could improve outcomes, but it does not test any treatment, cure, or prevention.
-
Design the FINnish ORAL Health Study in Long-Term Care study is a cross-sectional clinical research comprising findings on oral and general health and nutrition.
Why it matters
This cross-sectional study of 349 long-term care residents found a significant linear relationship between signs of oral frailty and Fried's frailty phenotype, with dementia prevalence increasing across oral frailty groups. It is about oral health and frailty in long-term care, not about treating, curing or preventing Alzheimer's disease.
-
49/100
Dual-task gait and other detailed gait metrics provide value for identifying CF above gait speed alone.
Why it matters
This study found that wearable sensors detected worse gait performance in older adults with cognitive frailty compared to those without it. It suggests gait measures as potential digital markers, not a treatment, cure, or prevention for Alzheimer's disease.
-
Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index.
Why it matters
This study describes characteristics of patients with Parkinson's disease who were newly diagnosed with cognitive impairment, including more hospitalizations and higher healthcare costs. It does not test any treatment, cure, or prevention for Alzheimer's disease, and it supports early diagnosis and management of cognitive impairment in Parkinson's disease.
-
Use of the transactional model of stress responses yielded important insights about families coping with dementia.
Why it matters
Among 53 rural family caregivers of people with dementia, those more worried about COVID-19 and those with insufficient support from family and friends were more likely to experience high role overload. This concerns caregiver wellbeing during the pandemic, not the treatment, cure, or prevention of Alzheimer's disease.
-
By 2040 more people in Scotland are projected to die with palliative care needs, and the complexity of need will increase markedly.
Why it matters
This mixed-method study projects that by 2040, the number of people in Scotland requiring palliative care will increase by at least 14%, or 20% when factoring in multimorbidity. The proportion of people dying from multiple diseases from different groups is projected to rise from 27% in 2017 to 43% by 2040, indicating service delivery models must adapt to growing demand and complexity.
-
Age and female sex are risk factors for dementia, and menopause is associated with cognitive dysfunction.
Why it matters
This cross-sectional UK Biobank study examined whether age interacts with sex or menopause in explaining imaging biomarkers of dementia during midlife. It is cross-sectional, so it cannot show that any treatment or intervention would prevent dementia.
-
Twenty-five of 33 (75.8%) participants in the qigong group and 26 of 33 (78.8%) participants in the control group completed the 1-year exercise programs.
Why it matters
One year of qigong practice was better than stretching exercise for preventing cognitive decline and improving some cognitive functions in older Chinese adults at risk of cognitive decline. This is an exercise program, not a cure, and it was tested in a specific group of older adults.
-
Our results demonstrate that the repeatability of speech features extracted using open-source tool kits is low.
Why it matters
This study found that commonly used open-source speech features had low repeatability across healthy controls and patients with ALS or suspected frontotemporal dementia. It is a caution about measurement methods and reports no treatment or prevention.
-
49/100
The duration and lifetime pattern of hypertension is related to risk of stroke and dementia.
Why it matters
This study examined how blood pressure patterns in mid and late life relate to cerebral small vessel disease, the most frequent cerebrovascular disease underlying dementia and stroke, in 1686 Framingham Heart Study participants. It is an observational study, so it can inform understanding of hypertension's role but cannot show that treating hypertension prevents dementia.
-
This study aimed to examine the associations between nursing home (NH) quality and prevalence of newly admitted NH residents with Alzheimer's disease and related dementias (ADRD), and to assess the extent to which market-level wages for certified nursing assistants (CNAs) and state Medicaid behavioral and mental health add-on policy may influence such associations.
Why it matters
This study found that high-quality nursing homes had a slightly lower prevalence of newly admitted residents with dementia, and that higher certified nursing assistant wages were linked to lower prevalence. It describes market and policy factors related to nursing home admissions, not treatment or cure.
-
Due to the COVID-19 pandemic, most memory clinics have had to suspend their activities.
Why it matters
This paper argues that telemedicine and digital devices like smartphones and videoconference apps could be used for remote follow-up and support of patients and caregivers when memory clinics cannot run normally. It does not report any treatment, cure, or prevention of Alzheimer's disease.
-
The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer's disease, frailty, Parkinson's, and cardiovascular disease, but also a general need for general eldercare as well as active and healthy ageing.
Why it matters
This literature review examines IoT wearable sensors and devices for monitoring, assessment, and support in elderly care, including dementia. It reports no treatment, cure, or prevention of Alzheimer's disease.
-
While all groups are affected by the COVID-19 pandemic, the elderly, underrepresented minorities, and those with underlying medical conditions are at the greatest risk.
Why it matters
This paper proposes that inflammation from COVID-19 may have long-term consequences in people who recover, potentially contributing to conditions such as dementia through neuroinflammatory mechanisms. It suggests that healthy eating habits and wider access to healthy foods could reduce susceptibility to and long-term complications from COVID-19, but this is a hypothesis rather than a demonstrated dementia treatment or prevention.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials
- Delirium prevalence and incidence in acutely admitted older patients: an observational cohort study
- Parental family history of dementia in relation to subclinical brain disease and dementia risk
- Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association
- Cognitive resilience to apolipoprotein E ε4: contributing factors in black and white older adults
- A systematic review of the association between the Behavioral and Psychological Symptoms of Dementia and burden of care
- Longitudinal Changes in Hearing and Visual Impairments and Risk of Dementia in Older Adults in the United States
- Brain age in bipolar disorders: Effects of lithium treatment
- The Healthy Mind, Healthy Mobility Trial: A Novel Exercise Program for Older Adults
- Achieving consensus and controversy around applicability of palliative care to dementia